CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
January 9, 2022 — 10:09 CST
This Data Is Locked!
This area is available only to Subscribers.
TIANJIN, China, Jan. 9, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China ("NMPA")... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
